Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or a left ventricular assist device (LVAD).

News | Cardiac Resynchronization Therapy Devices (CRT)

Leadless CRT Can Deliver Left Bundle Branch Area Pacing for Cardiac Resynchronization

October 27, 2021 — EBR Systems Inc., developer of the world’s first wireless cardiac pacing system for heart failure, ...

October 27, 2021

The CorWave LVAD uses a pulse pump rather than a rotary pump to move blood, so it more closely simulates the movement of blood in a read heart.

News | Ventricular Assist Devices (VAD)

Innovative New Pulsatile LVAD Wins 2021 HealthTech Award

October 20, 2021 – CorWave, a French medtech company developing a next-generation heart pump, won the 2021 HealthTech ...

October 20, 2021

$FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction. he U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for empagliflozin (Jardiance) as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF).$

News | Pharmaceuticals

FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction

October 7, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for ...

October 07, 2021

Sponsored Content

Blog | Artificial Intelligence

BLOG: AI outperforms human analysis in predicting cardiac outcomes

New research shows superiority of Ultromics’ AI in predicting cardiac-related death As the use of artificial ...

October 10, 2022

SimpleSense is an FDA cleared remote diagnostic platform. The cloth-based nanosensor technology undergarment monitors multiple patient vitals such as heart rate, blood pressure, respiration rate, and physical activity.

News | Cardiac Diagnostics

FDA Clears Nanowear Platform to Implement AI-based Home Diagnostics and Monitoring Network

October 4, 2021 – Nanowear, a hospital-at-home and remote diagnostic platform that used proprietary wearable cloth ...

October 04, 2021

Videos | Stem Cell Therapies

VIDEO: Engineered Heart Tissue Aids Research With a Heart in a Dish System

Mechanical engineering Professor Nathan Sniadecki, associate chair for research and infrastructure, mechanical ...

October 04, 2021

$A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line at the European Society of Cardiology (ESC) 2021 Congress, and was published in the New England Journal of Medicine. Data from the EMPEROR-Preserved and in EMPEROR-Reduced trials.$

News | Heart Failure

Empagliflozin Benefits Heart Failure Patients With Reduced and Preserved Ejection Fraction

October 1, 2021 — A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in ...

October 04, 2021

CardioMEMS is a wireless, battery-free sensor that is implanted into the pulmonary artery via a right heart catheterization procedure to transmit pulmonary artery pressures.

News | Heart Failure

GUIDE-HF Trial Shows Hemodynamic Guided Management Benefits Larger Heart Failure Population

September 28, 2021 — Hemodynamic guided management using the CardioMEMS device may reduce heart failure hospitalizations ...

September 28, 2021

Cardiothoracic surgeons with UofL Health – Jewish Hospital and the University of Louisville performed the world’s first Carmat Aeson bioprosthetic total artificial heart implantation in a female patient on Sept. 14, 2021. The device was small enough to fit into the woman's smaller chest cavity. The device is being tested as a bridge to heart transplant rather than use of a LVAD. Photo by UofL Health.

News | Heart Failure

First Woman in World Receives New Type of Artificial Heart

September 22, 2021 — A cardiothoracic surgical team with University of Louisville Health – Jewish Hospital has performed ...

September 22, 2021

News | Heart Failure

ESC Releases Guidelines on Heart Failure Management

September 21, 2021 — The European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and ...

September 21, 2021

The American Heart Association announced its support this week for the CDC and FDA recommendation that immuno-compromised patients should receive a third dose of the Pfizer or Moderna COVID vaccines. Getty Images #AHA #coronavirus #COVID19

News | Coronavirus (COVID-19) | By Dave Fornell, Editor

American Heart Association Supports COVID Vaccine Boosters Suggested by the CDC

August 18, 2021 — The U.S. Centers for Disease Control and Prevention (CDC) recommended Friday a third dose of the ...

August 18, 2021

BIO-AffectDX is a multi-center, observational study that will enroll HF patients with paroxysmal, persistent and long-standing persistent AF, and a standard CRT-D indication. The study will include up to 400 participants implanted with a Biotronik Acticor CRT-DX system.

News | Cardiac Resynchronization Therapy Devices (CRT)

New Study Aims to Show Effectiveness of CRT-D for Heart Failure Patients With Atrial Fibrillation

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...

August 03, 2021

Medtronic announced in June it was stopping the sale and distribution of the Medtronic Heartware HVAD left ventricular assist device (LVAD). Abbott announced the same day it has the capacity to meet increased demand for LVADs as Medtronic leaves the market.

Feature | Ventricular Assist Devices (VAD) | By Dave Fornell, Editor

Medtronic Ends Sales of HVAD Ventricular Assist System

Medtronic announced in June it was stopping the sale and distribution of the Medtronic Heartware HVAD left ventricular ...

July 08, 2021

The Carmat system, an experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can adjust to the changing needs of patients treated for end-stage heart failure. Outcomes in the first series of patients managed with the new heart replacement pump in Auto-Mode are presented in the journal of the American Society for Artificial Internal Organs (ASAIO).

News | Artificial Heart

Carmat Artificial Heart Shows Promising Automatic Regulation of Blood Flow

June 18, 2021 – An experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can ...

June 23, 2021

NIVAHF is an investigational device designed to monitor the venous waveform, a novel physiologic signal, in heart failure patients

News | Heart Failure

VoluMetrix's NIVA|HF for Heart Failure Patients Designated as Breakthrough Device by U.S. FDA

June 15, 2021 — VoluMetrix, a Nashville-based biotech startup dedicated to creating a new wave of solutions for vital ...

June 15, 2021

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.

Feature | ACC | By Dave Fornell, Editor

Key Cardiology Technology Takeaways at ACC 2021

Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 Americ ...

June 08, 2021